Global Biologics for Severe Asthma Market Growth 2026-2032
The global Biologics for Severe Asthma market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Biologics for severe asthma are a class of drugs used to treat severe asthma. These drugs mainly work by regulating the immune system to reduce inflammation and control asthma symptoms.
United States market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Biologics for Severe Asthma players cover AstraZeneca, Amgen, Roche, Novartis, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Biologics for Severe Asthma Industry Forecast? looks at past sales and reviews total world Biologics for Severe Asthma sales in 2025, providing a comprehensive analysis by region and market sector of projected Biologics for Severe Asthma sales for 2026 through 2032. With Biologics for Severe Asthma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics for Severe Asthma industry.
This Insight Report provides a comprehensive analysis of the global Biologics for Severe Asthma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics for Severe Asthma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Biologics for Severe Asthma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics for Severe Asthma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics for Severe Asthma.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics for Severe Asthma market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Biologics for severe asthma are a class of drugs used to treat severe asthma. These drugs mainly work by regulating the immune system to reduce inflammation and control asthma symptoms.
United States market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Biologics for Severe Asthma is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Biologics for Severe Asthma players cover AstraZeneca, Amgen, Roche, Novartis, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Biologics for Severe Asthma Industry Forecast? looks at past sales and reviews total world Biologics for Severe Asthma sales in 2025, providing a comprehensive analysis by region and market sector of projected Biologics for Severe Asthma sales for 2026 through 2032. With Biologics for Severe Asthma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics for Severe Asthma industry.
This Insight Report provides a comprehensive analysis of the global Biologics for Severe Asthma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics for Severe Asthma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Biologics for Severe Asthma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics for Severe Asthma and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics for Severe Asthma.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics for Severe Asthma market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Omalizumab
- Benralizumab
- Dupirumab
- Mepolizumab
- Reslizumab
- Tezepelumab-ekko
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Amgen
- Roche
- Novartis
- Sanofi
- Regeneron Pharmaceuticals
- GSK
- Teva Pharmaceuticals
- What is the 10-year outlook for the global Biologics for Severe Asthma market?
- What factors are driving Biologics for Severe Asthma market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How doBiologics for Severe Asthma market opportunities vary by end market size?
- How does Biologics for Severe Asthma break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biologics for Severe Asthma Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Biologics for Severe Asthma by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Biologics for Severe Asthma by Country/Region, 2021, 2025 & 2032
2.2 Biologics for Severe Asthma Segment by Type
2.2.1 Omalizumab
2.2.2 Benralizumab
2.2.3 Dupirumab
2.2.4 Mepolizumab
2.2.5 Reslizumab
2.2.6 Tezepelumab-ekko
2.2.7 Biologics for Severe Asthma Sales by Type
2.2.7.1 Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
2.2.7.2 Global Biologics for Severe Asthma Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Biologics for Severe Asthma Sale Price by Type (2021-2026)
2.3 Biologics for Severe Asthma Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 Biologics for Severe Asthma Sales by Application
2.3.4.1 Global Biologics for Severe Asthma Sale Market Share by Application (2021-2026)
2.3.4.2 Global Biologics for Severe Asthma Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Biologics for Severe Asthma Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Biologics for Severe Asthma Breakdown Data by Company
3.1.1 Global Biologics for Severe Asthma Annual Sales by Company (2021-2026)
3.1.2 Global Biologics for Severe Asthma Sales Market Share by Company (2021-2026)
3.2 Global Biologics for Severe Asthma Annual Revenue by Company (2021-2026)
3.2.1 Global Biologics for Severe Asthma Revenue by Company (2021-2026)
3.2.2 Global Biologics for Severe Asthma Revenue Market Share by Company (2021-2026)
3.3 Global Biologics for Severe Asthma Sale Price by Company
3.4 Key Manufacturers Biologics for Severe Asthma Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologics for Severe Asthma Product Location Distribution
3.4.2 Players Biologics for Severe Asthma Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOLOGICS FOR SEVERE ASTHMA BY GEOGRAPHIC REGION
4.1 World Historic Biologics for Severe Asthma Market Size by Geographic Region (2021-2026)
4.1.1 Global Biologics for Severe Asthma Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Biologics for Severe Asthma Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Biologics for Severe Asthma Market Size by Country/Region (2021-2026)
4.2.1 Global Biologics for Severe Asthma Annual Sales by Country/Region (2021-2026)
4.2.2 Global Biologics for Severe Asthma Annual Revenue by Country/Region (2021-2026)
4.3 Americas Biologics for Severe Asthma Sales Growth
4.4 APAC Biologics for Severe Asthma Sales Growth
4.5 Europe Biologics for Severe Asthma Sales Growth
4.6 Middle East & Africa Biologics for Severe Asthma Sales Growth
5 AMERICAS
5.1 Americas Biologics for Severe Asthma Sales by Country
5.1.1 Americas Biologics for Severe Asthma Sales by Country (2021-2026)
5.1.2 Americas Biologics for Severe Asthma Revenue by Country (2021-2026)
5.2 Americas Biologics for Severe Asthma Sales by Type (2021-2026)
5.3 Americas Biologics for Severe Asthma Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics for Severe Asthma Sales by Region
6.1.1 APAC Biologics for Severe Asthma Sales by Region (2021-2026)
6.1.2 APAC Biologics for Severe Asthma Revenue by Region (2021-2026)
6.2 APAC Biologics for Severe Asthma Sales by Type (2021-2026)
6.3 APAC Biologics for Severe Asthma Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biologics for Severe Asthma by Country
7.1.1 Europe Biologics for Severe Asthma Sales by Country (2021-2026)
7.1.2 Europe Biologics for Severe Asthma Revenue by Country (2021-2026)
7.2 Europe Biologics for Severe Asthma Sales by Type (2021-2026)
7.3 Europe Biologics for Severe Asthma Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biologics for Severe Asthma by Country
8.1.1 Middle East & Africa Biologics for Severe Asthma Sales by Country (2021-2026)
8.1.2 Middle East & Africa Biologics for Severe Asthma Revenue by Country (2021-2026)
8.2 Middle East & Africa Biologics for Severe Asthma Sales by Type (2021-2026)
8.3 Middle East & Africa Biologics for Severe Asthma Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologics for Severe Asthma
10.3 Manufacturing Process Analysis of Biologics for Severe Asthma
10.4 Industry Chain Structure of Biologics for Severe Asthma
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologics for Severe Asthma Distributors
11.3 Biologics for Severe Asthma Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICS FOR SEVERE ASTHMA BY GEOGRAPHIC REGION
12.1 Global Biologics for Severe Asthma Market Size Forecast by Region
12.1.1 Global Biologics for Severe Asthma Forecast by Region (2027-2032)
12.1.2 Global Biologics for Severe Asthma Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Biologics for Severe Asthma Forecast by Type (2027-2032)
12.7 Global Biologics for Severe Asthma Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Biologics for Severe Asthma Product Portfolios and Specifications
13.1.3 AstraZeneca Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Biologics for Severe Asthma Product Portfolios and Specifications
13.2.3 Amgen Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Biologics for Severe Asthma Product Portfolios and Specifications
13.3.3 Roche Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Biologics for Severe Asthma Product Portfolios and Specifications
13.4.3 Novartis Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Biologics for Severe Asthma Product Portfolios and Specifications
13.5.3 Sanofi Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Regeneron Pharmaceuticals
13.6.1 Regeneron Pharmaceuticals Company Information
13.6.2 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
13.6.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Pharmaceuticals Main Business Overview
13.6.5 Regeneron Pharmaceuticals Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biologics for Severe Asthma Product Portfolios and Specifications
13.7.3 GSK Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 Teva Pharmaceuticals
13.8.1 Teva Pharmaceuticals Company Information
13.8.2 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
13.8.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Teva Pharmaceuticals Main Business Overview
13.8.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biologics for Severe Asthma Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Biologics for Severe Asthma by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Biologics for Severe Asthma by Country/Region, 2021, 2025 & 2032
2.2 Biologics for Severe Asthma Segment by Type
2.2.1 Omalizumab
2.2.2 Benralizumab
2.2.3 Dupirumab
2.2.4 Mepolizumab
2.2.5 Reslizumab
2.2.6 Tezepelumab-ekko
2.2.7 Biologics for Severe Asthma Sales by Type
2.2.7.1 Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
2.2.7.2 Global Biologics for Severe Asthma Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Biologics for Severe Asthma Sale Price by Type (2021-2026)
2.3 Biologics for Severe Asthma Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 Biologics for Severe Asthma Sales by Application
2.3.4.1 Global Biologics for Severe Asthma Sale Market Share by Application (2021-2026)
2.3.4.2 Global Biologics for Severe Asthma Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Biologics for Severe Asthma Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Biologics for Severe Asthma Breakdown Data by Company
3.1.1 Global Biologics for Severe Asthma Annual Sales by Company (2021-2026)
3.1.2 Global Biologics for Severe Asthma Sales Market Share by Company (2021-2026)
3.2 Global Biologics for Severe Asthma Annual Revenue by Company (2021-2026)
3.2.1 Global Biologics for Severe Asthma Revenue by Company (2021-2026)
3.2.2 Global Biologics for Severe Asthma Revenue Market Share by Company (2021-2026)
3.3 Global Biologics for Severe Asthma Sale Price by Company
3.4 Key Manufacturers Biologics for Severe Asthma Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologics for Severe Asthma Product Location Distribution
3.4.2 Players Biologics for Severe Asthma Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOLOGICS FOR SEVERE ASTHMA BY GEOGRAPHIC REGION
4.1 World Historic Biologics for Severe Asthma Market Size by Geographic Region (2021-2026)
4.1.1 Global Biologics for Severe Asthma Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Biologics for Severe Asthma Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Biologics for Severe Asthma Market Size by Country/Region (2021-2026)
4.2.1 Global Biologics for Severe Asthma Annual Sales by Country/Region (2021-2026)
4.2.2 Global Biologics for Severe Asthma Annual Revenue by Country/Region (2021-2026)
4.3 Americas Biologics for Severe Asthma Sales Growth
4.4 APAC Biologics for Severe Asthma Sales Growth
4.5 Europe Biologics for Severe Asthma Sales Growth
4.6 Middle East & Africa Biologics for Severe Asthma Sales Growth
5 AMERICAS
5.1 Americas Biologics for Severe Asthma Sales by Country
5.1.1 Americas Biologics for Severe Asthma Sales by Country (2021-2026)
5.1.2 Americas Biologics for Severe Asthma Revenue by Country (2021-2026)
5.2 Americas Biologics for Severe Asthma Sales by Type (2021-2026)
5.3 Americas Biologics for Severe Asthma Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics for Severe Asthma Sales by Region
6.1.1 APAC Biologics for Severe Asthma Sales by Region (2021-2026)
6.1.2 APAC Biologics for Severe Asthma Revenue by Region (2021-2026)
6.2 APAC Biologics for Severe Asthma Sales by Type (2021-2026)
6.3 APAC Biologics for Severe Asthma Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biologics for Severe Asthma by Country
7.1.1 Europe Biologics for Severe Asthma Sales by Country (2021-2026)
7.1.2 Europe Biologics for Severe Asthma Revenue by Country (2021-2026)
7.2 Europe Biologics for Severe Asthma Sales by Type (2021-2026)
7.3 Europe Biologics for Severe Asthma Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biologics for Severe Asthma by Country
8.1.1 Middle East & Africa Biologics for Severe Asthma Sales by Country (2021-2026)
8.1.2 Middle East & Africa Biologics for Severe Asthma Revenue by Country (2021-2026)
8.2 Middle East & Africa Biologics for Severe Asthma Sales by Type (2021-2026)
8.3 Middle East & Africa Biologics for Severe Asthma Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologics for Severe Asthma
10.3 Manufacturing Process Analysis of Biologics for Severe Asthma
10.4 Industry Chain Structure of Biologics for Severe Asthma
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologics for Severe Asthma Distributors
11.3 Biologics for Severe Asthma Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICS FOR SEVERE ASTHMA BY GEOGRAPHIC REGION
12.1 Global Biologics for Severe Asthma Market Size Forecast by Region
12.1.1 Global Biologics for Severe Asthma Forecast by Region (2027-2032)
12.1.2 Global Biologics for Severe Asthma Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Biologics for Severe Asthma Forecast by Type (2027-2032)
12.7 Global Biologics for Severe Asthma Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Biologics for Severe Asthma Product Portfolios and Specifications
13.1.3 AstraZeneca Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Biologics for Severe Asthma Product Portfolios and Specifications
13.2.3 Amgen Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Biologics for Severe Asthma Product Portfolios and Specifications
13.3.3 Roche Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Biologics for Severe Asthma Product Portfolios and Specifications
13.4.3 Novartis Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Biologics for Severe Asthma Product Portfolios and Specifications
13.5.3 Sanofi Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Regeneron Pharmaceuticals
13.6.1 Regeneron Pharmaceuticals Company Information
13.6.2 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
13.6.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Pharmaceuticals Main Business Overview
13.6.5 Regeneron Pharmaceuticals Latest Developments
13.7 GSK
13.7.1 GSK Company Information
13.7.2 GSK Biologics for Severe Asthma Product Portfolios and Specifications
13.7.3 GSK Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 GSK Main Business Overview
13.7.5 GSK Latest Developments
13.8 Teva Pharmaceuticals
13.8.1 Teva Pharmaceuticals Company Information
13.8.2 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
13.8.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Teva Pharmaceuticals Main Business Overview
13.8.5 Teva Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Biologics for Severe Asthma Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Biologics for Severe Asthma Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Omalizumab
Table 4. Major Players of Benralizumab
Table 5. Major Players of Dupirumab
Table 6. Major Players of Mepolizumab
Table 7. Major Players of Reslizumab
Table 8. Major Players of Tezepelumab-ekko
Table 9. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 10. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Table 11. Global Biologics for Severe Asthma Revenue by Type (2021-2026) & ($ million)
Table 12. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026)
Table 13. Global Biologics for Severe Asthma Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Biologics for Severe Asthma Sale by Application (2021-2026) & (K Units)
Table 15. Global Biologics for Severe Asthma Sale Market Share by Application (2021-2026)
Table 16. Global Biologics for Severe Asthma Revenue by Application (2021-2026) & ($ million)
Table 17. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2026)
Table 18. Global Biologics for Severe Asthma Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global Biologics for Severe Asthma Sales by Company (2021-2026) & (K Units)
Table 20. Global Biologics for Severe Asthma Sales Market Share by Company (2021-2026)
Table 21. Global Biologics for Severe Asthma Revenue by Company (2021-2026) & ($ millions)
Table 22. Global Biologics for Severe Asthma Revenue Market Share by Company (2021-2026)
Table 23. Global Biologics for Severe Asthma Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers Biologics for Severe Asthma Producing Area Distribution and Sales Area
Table 25. Players Biologics for Severe Asthma Products Offered
Table 26. Biologics for Severe Asthma Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Biologics for Severe Asthma Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global Biologics for Severe Asthma Sales Market Share Geographic Region (2021-2026)
Table 31. Global Biologics for Severe Asthma Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global Biologics for Severe Asthma Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global Biologics for Severe Asthma Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global Biologics for Severe Asthma Sales Market Share by Country/Region (2021-2026)
Table 35. Global Biologics for Severe Asthma Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Biologics for Severe Asthma Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 38. Americas Biologics for Severe Asthma Sales Market Share by Country (2021-2026)
Table 39. Americas Biologics for Severe Asthma Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 41. Americas Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 42. APAC Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units)
Table 43. APAC Biologics for Severe Asthma Sales Market Share by Region (2021-2026)
Table 44. APAC Biologics for Severe Asthma Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 46. APAC Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 47. Europe Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 48. Europe Biologics for Severe Asthma Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 50. Europe Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Biologics for Severe Asthma
Table 56. Key Market Challenges & Risks of Biologics for Severe Asthma
Table 57. Key Industry Trends of Biologics for Severe Asthma
Table 58. Biologics for Severe Asthma Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Biologics for Severe Asthma Distributors List
Table 61. Biologics for Severe Asthma Customer List
Table 62. Global Biologics for Severe Asthma Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global Biologics for Severe Asthma Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas Biologics for Severe Asthma Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC Biologics for Severe Asthma Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC Biologics for Severe Asthma Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe Biologics for Severe Asthma Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa Biologics for Severe Asthma Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global Biologics for Severe Asthma Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global Biologics for Severe Asthma Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global Biologics for Severe Asthma Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global Biologics for Severe Asthma Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. AstraZeneca Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 77. AstraZeneca Biologics for Severe Asthma Product Portfolios and Specifications
Table 78. AstraZeneca Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. AstraZeneca Main Business
Table 80. AstraZeneca Latest Developments
Table 81. Amgen Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 82. Amgen Biologics for Severe Asthma Product Portfolios and Specifications
Table 83. Amgen Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Amgen Main Business
Table 85. Amgen Latest Developments
Table 86. Roche Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 87. Roche Biologics for Severe Asthma Product Portfolios and Specifications
Table 88. Roche Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Roche Main Business
Table 90. Roche Latest Developments
Table 91. Novartis Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Biologics for Severe Asthma Product Portfolios and Specifications
Table 93. Novartis Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Sanofi Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 97. Sanofi Biologics for Severe Asthma Product Portfolios and Specifications
Table 98. Sanofi Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sanofi Main Business
Table 100. Sanofi Latest Developments
Table 101. Regeneron Pharmaceuticals Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 102. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
Table 103. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Regeneron Pharmaceuticals Main Business
Table 105. Regeneron Pharmaceuticals Latest Developments
Table 106. GSK Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 107. GSK Biologics for Severe Asthma Product Portfolios and Specifications
Table 108. GSK Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. GSK Main Business
Table 110. GSK Latest Developments
Table 111. Teva Pharmaceuticals Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 112. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
Table 113. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Teva Pharmaceuticals Main Business
Table 115. Teva Pharmaceuticals Latest Developments
Table 1. Biologics for Severe Asthma Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Biologics for Severe Asthma Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Omalizumab
Table 4. Major Players of Benralizumab
Table 5. Major Players of Dupirumab
Table 6. Major Players of Mepolizumab
Table 7. Major Players of Reslizumab
Table 8. Major Players of Tezepelumab-ekko
Table 9. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 10. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Table 11. Global Biologics for Severe Asthma Revenue by Type (2021-2026) & ($ million)
Table 12. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026)
Table 13. Global Biologics for Severe Asthma Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Biologics for Severe Asthma Sale by Application (2021-2026) & (K Units)
Table 15. Global Biologics for Severe Asthma Sale Market Share by Application (2021-2026)
Table 16. Global Biologics for Severe Asthma Revenue by Application (2021-2026) & ($ million)
Table 17. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2026)
Table 18. Global Biologics for Severe Asthma Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global Biologics for Severe Asthma Sales by Company (2021-2026) & (K Units)
Table 20. Global Biologics for Severe Asthma Sales Market Share by Company (2021-2026)
Table 21. Global Biologics for Severe Asthma Revenue by Company (2021-2026) & ($ millions)
Table 22. Global Biologics for Severe Asthma Revenue Market Share by Company (2021-2026)
Table 23. Global Biologics for Severe Asthma Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers Biologics for Severe Asthma Producing Area Distribution and Sales Area
Table 25. Players Biologics for Severe Asthma Products Offered
Table 26. Biologics for Severe Asthma Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Biologics for Severe Asthma Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global Biologics for Severe Asthma Sales Market Share Geographic Region (2021-2026)
Table 31. Global Biologics for Severe Asthma Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global Biologics for Severe Asthma Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global Biologics for Severe Asthma Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global Biologics for Severe Asthma Sales Market Share by Country/Region (2021-2026)
Table 35. Global Biologics for Severe Asthma Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Biologics for Severe Asthma Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 38. Americas Biologics for Severe Asthma Sales Market Share by Country (2021-2026)
Table 39. Americas Biologics for Severe Asthma Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 41. Americas Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 42. APAC Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units)
Table 43. APAC Biologics for Severe Asthma Sales Market Share by Region (2021-2026)
Table 44. APAC Biologics for Severe Asthma Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 46. APAC Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 47. Europe Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 48. Europe Biologics for Severe Asthma Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 50. Europe Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Biologics for Severe Asthma
Table 56. Key Market Challenges & Risks of Biologics for Severe Asthma
Table 57. Key Industry Trends of Biologics for Severe Asthma
Table 58. Biologics for Severe Asthma Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Biologics for Severe Asthma Distributors List
Table 61. Biologics for Severe Asthma Customer List
Table 62. Global Biologics for Severe Asthma Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global Biologics for Severe Asthma Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas Biologics for Severe Asthma Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC Biologics for Severe Asthma Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC Biologics for Severe Asthma Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe Biologics for Severe Asthma Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa Biologics for Severe Asthma Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa Biologics for Severe Asthma Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global Biologics for Severe Asthma Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global Biologics for Severe Asthma Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global Biologics for Severe Asthma Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global Biologics for Severe Asthma Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. AstraZeneca Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 77. AstraZeneca Biologics for Severe Asthma Product Portfolios and Specifications
Table 78. AstraZeneca Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. AstraZeneca Main Business
Table 80. AstraZeneca Latest Developments
Table 81. Amgen Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 82. Amgen Biologics for Severe Asthma Product Portfolios and Specifications
Table 83. Amgen Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Amgen Main Business
Table 85. Amgen Latest Developments
Table 86. Roche Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 87. Roche Biologics for Severe Asthma Product Portfolios and Specifications
Table 88. Roche Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Roche Main Business
Table 90. Roche Latest Developments
Table 91. Novartis Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Biologics for Severe Asthma Product Portfolios and Specifications
Table 93. Novartis Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Sanofi Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 97. Sanofi Biologics for Severe Asthma Product Portfolios and Specifications
Table 98. Sanofi Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sanofi Main Business
Table 100. Sanofi Latest Developments
Table 101. Regeneron Pharmaceuticals Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 102. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
Table 103. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Regeneron Pharmaceuticals Main Business
Table 105. Regeneron Pharmaceuticals Latest Developments
Table 106. GSK Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 107. GSK Biologics for Severe Asthma Product Portfolios and Specifications
Table 108. GSK Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. GSK Main Business
Table 110. GSK Latest Developments
Table 111. Teva Pharmaceuticals Basic Information, Biologics for Severe Asthma Manufacturing Base, Sales Area and Its Competitors
Table 112. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolios and Specifications
Table 113. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Teva Pharmaceuticals Main Business
Table 115. Teva Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Biologics for Severe Asthma
Figure 2. Biologics for Severe Asthma Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biologics for Severe Asthma Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Biologics for Severe Asthma Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Biologics for Severe Asthma Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Biologics for Severe Asthma Sales Market Share by Country/Region (2025)
Figure 10. Biologics for Severe Asthma Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Omalizumab
Figure 12. Product Picture of Benralizumab
Figure 13. Product Picture of Dupirumab
Figure 14. Product Picture of Mepolizumab
Figure 15. Product Picture of Reslizumab
Figure 16. Product Picture of Tezepelumab-ekko
Figure 17. Global Biologics for Severe Asthma Sales Market Share by Type in 2026
Figure 18. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026)
Figure 19. Biologics for Severe Asthma Consumed in Hospital
Figure 20. Global Biologics for Severe Asthma Market: Hospital (2021-2026) & (K Units)
Figure 21. Biologics for Severe Asthma Consumed in Clinic
Figure 22. Global Biologics for Severe Asthma Market: Clinic (2021-2026) & (K Units)
Figure 23. Biologics for Severe Asthma Consumed in Other
Figure 24. Global Biologics for Severe Asthma Market: Other (2021-2026) & (K Units)
Figure 25. Global Biologics for Severe Asthma Sale Market Share by Application (2025)
Figure 26. Global Biologics for Severe Asthma Revenue Market Share by Application in 2026
Figure 27. Biologics for Severe Asthma Sales by Company in 2026 (K Units)
Figure 28. Global Biologics for Severe Asthma Sales Market Share by Company in 2026
Figure 29. Biologics for Severe Asthma Revenue by Company in 2026 ($ millions)
Figure 30. Global Biologics for Severe Asthma Revenue Market Share by Company in 2026
Figure 31. Global Biologics for Severe Asthma Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Biologics for Severe Asthma Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 34. Americas Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 35. APAC Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 36. APAC Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 37. Europe Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 38. Europe Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 41. Americas Biologics for Severe Asthma Sales Market Share by Country in 2026
Figure 42. Americas Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Figure 43. Americas Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 44. Americas Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 45. United States Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Biologics for Severe Asthma Sales Market Share by Region in 2026
Figure 50. APAC Biologics for Severe Asthma Revenue Market Share by Region (2021-2026)
Figure 51. APAC Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 52. APAC Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 53. China Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 57. India Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Biologics for Severe Asthma Sales Market Share by Country in 2026
Figure 61. Europe Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Figure 62. Europe Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 63. Europe Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 64. Germany Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 65. France Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 72. Egypt Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Biologics for Severe Asthma in 2026
Figure 78. Manufacturing Process Analysis of Biologics for Severe Asthma
Figure 79. Industry Chain Structure of Biologics for Severe Asthma
Figure 80. Channels of Distribution
Figure 81. Global Biologics for Severe Asthma Sales Market Forecast by Region (2027-2032)
Figure 82. Global Biologics for Severe Asthma Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Biologics for Severe Asthma Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Biologics for Severe Asthma Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Biologics for Severe Asthma Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Biologics for Severe Asthma Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Biologics for Severe Asthma
Figure 2. Biologics for Severe Asthma Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biologics for Severe Asthma Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Biologics for Severe Asthma Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Biologics for Severe Asthma Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Biologics for Severe Asthma Sales Market Share by Country/Region (2025)
Figure 10. Biologics for Severe Asthma Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Omalizumab
Figure 12. Product Picture of Benralizumab
Figure 13. Product Picture of Dupirumab
Figure 14. Product Picture of Mepolizumab
Figure 15. Product Picture of Reslizumab
Figure 16. Product Picture of Tezepelumab-ekko
Figure 17. Global Biologics for Severe Asthma Sales Market Share by Type in 2026
Figure 18. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026)
Figure 19. Biologics for Severe Asthma Consumed in Hospital
Figure 20. Global Biologics for Severe Asthma Market: Hospital (2021-2026) & (K Units)
Figure 21. Biologics for Severe Asthma Consumed in Clinic
Figure 22. Global Biologics for Severe Asthma Market: Clinic (2021-2026) & (K Units)
Figure 23. Biologics for Severe Asthma Consumed in Other
Figure 24. Global Biologics for Severe Asthma Market: Other (2021-2026) & (K Units)
Figure 25. Global Biologics for Severe Asthma Sale Market Share by Application (2025)
Figure 26. Global Biologics for Severe Asthma Revenue Market Share by Application in 2026
Figure 27. Biologics for Severe Asthma Sales by Company in 2026 (K Units)
Figure 28. Global Biologics for Severe Asthma Sales Market Share by Company in 2026
Figure 29. Biologics for Severe Asthma Revenue by Company in 2026 ($ millions)
Figure 30. Global Biologics for Severe Asthma Revenue Market Share by Company in 2026
Figure 31. Global Biologics for Severe Asthma Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Biologics for Severe Asthma Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 34. Americas Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 35. APAC Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 36. APAC Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 37. Europe Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 38. Europe Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Biologics for Severe Asthma Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Biologics for Severe Asthma Revenue 2021-2026 ($ millions)
Figure 41. Americas Biologics for Severe Asthma Sales Market Share by Country in 2026
Figure 42. Americas Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Figure 43. Americas Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 44. Americas Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 45. United States Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Biologics for Severe Asthma Sales Market Share by Region in 2026
Figure 50. APAC Biologics for Severe Asthma Revenue Market Share by Region (2021-2026)
Figure 51. APAC Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 52. APAC Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 53. China Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 57. India Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Biologics for Severe Asthma Sales Market Share by Country in 2026
Figure 61. Europe Biologics for Severe Asthma Revenue Market Share by Country (2021-2026)
Figure 62. Europe Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 63. Europe Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 64. Germany Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 65. France Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Biologics for Severe Asthma Sales Market Share by Application (2021-2026)
Figure 72. Egypt Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Biologics for Severe Asthma Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Biologics for Severe Asthma in 2026
Figure 78. Manufacturing Process Analysis of Biologics for Severe Asthma
Figure 79. Industry Chain Structure of Biologics for Severe Asthma
Figure 80. Channels of Distribution
Figure 81. Global Biologics for Severe Asthma Sales Market Forecast by Region (2027-2032)
Figure 82. Global Biologics for Severe Asthma Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Biologics for Severe Asthma Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Biologics for Severe Asthma Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Biologics for Severe Asthma Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Biologics for Severe Asthma Revenue Market Share Forecast by Application (2027-2032)
